- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Highlights:** For Q2 FY25, Borosil Scientific reported net sales of ₹102.6 Cr, an 11.6% increase YoY, while EBITDA rose to ₹17.4 Cr, reflecting a 59.4% growth, with an improved EBITDA margin of 16.9%. The PAT surged dramatically from ₹5.0 Cr to ₹8.8 Cr, marking a 74.5% growth, supported by reduced net debt, indicating strong financial health.
**Strategic Initiatives and Growth Drivers:** The company has entered into the pharmaceutical primary packaging market through the acquisition of Klasspack, enhancing its product portfolio. Focus remains on the domestic market and expanding exports, leveraging the ‘Make in India’ initiative to drive growth.
**Business Developments:** Borosil has made a strategic acquisition of Goel Scientific Glass Works and is actively shifting its manufacturing base to Bharuch, which is expected to improve operational efficiency and production capacity.
**Market Position and Competitive Advantage:** Borosil Scientific holds a strong market position in laboratory glassware and equipment, with extensive distribution across more than 90 countries. Its established brand is synonymous with quality in the scientific community.
**Investor Implications:** With a positive outlook driven by strategic expansions and strong financial performance, Borosil Scientific presents potential growth opportunities for investors seeking exposure in the scientific equipment market. The company targets a revenue CAGR of 12-14%, reinforcing its commitment to long-term profitability.